Drug-Induced Movement Disorders The purpose of this article is to present a general overview of the features of drug-induced movement disorders (DIMDs) comprised by Parkinsonism and extrapyramidal symptoms. Speech-language pathologists (SLPs) who work with patients presenting with these issues must have a broad understanding of the underlying disease process. This article will provide ... Article
Article  |   April 01, 2015
Drug-Induced Movement Disorders
Amy Lustig and Cesar Ruiz
Author Affiliations & Notes
  • Amy Lustig
    Private Speech Pathology Practice, Restorative Speech & Swallow, LLC, Jenkintown, PA
  • Cesar Ruiz
    Speech-Language-Hearing Science Program, La Salle University, Philadelphia, PA
  • Financial Disclosure: Amy Lustig is owner of Restorative Speech & Swallow, LLC. Cesar Ruiz is an associate professor at La Salle University.
    Financial Disclosure: Amy Lustig is owner of Restorative Speech & Swallow, LLC. Cesar Ruiz is an associate professor at La Salle University.×
  • Nonfinancial Disclosure: Amy Lustig has previously published in the subject area. Cesar Ruiz has no nonfinancial interests related to the content of this article.
    Nonfinancial Disclosure: Amy Lustig has previously published in the subject area. Cesar Ruiz has no nonfinancial interests related to the content of this article.×
  • Copyright © 2015 American Speech-Language-Hearing Association
Article Information
Swallowing, Dysphagia & Feeding Disorders / Special Populations / Older Adults & Aging / Articles
Article   |   April 01, 2015
Drug-Induced Movement Disorders
SIG 2 Perspectives on Neurophysiology and Neurogenic Speech and Language Disorders, April 2015, Vol. 25, 70-77. doi:10.1044/nnsld25.2.70
History: Received December 22, 2014 , Revised February 24, 2015 , Accepted March 19, 2015
SIG 2 Perspectives on Neurophysiology and Neurogenic Speech and Language Disorders, April 2015, Vol. 25, 70-77. doi:10.1044/nnsld25.2.70
History: Received December 22, 2014; Revised February 24, 2015; Accepted March 19, 2015

The purpose of this article is to present a general overview of the features of drug-induced movement disorders (DIMDs) comprised by Parkinsonism and extrapyramidal symptoms. Speech-language pathologists (SLPs) who work with patients presenting with these issues must have a broad understanding of the underlying disease process. This article will provide a brief introduction to the neuropathophysiology of DIMDs, a discussion of the associated symptomatology, the pharmacology implicated in causing DIMDs, and the medical management approaches currently in use.

Become a SIG Affiliate
Join a SIG
Pay Per View
Entire SIG 2 Perspectives on Neurophysiology and Neurogenic Speech and Language Disorders content & archive
24-hour access
This Issue
24-hour access
This Article
24-hour access
We've Changed Our Publication Model...
The 19 individual SIG Perspectives publications have been relaunched as the new, all-in-one Perspectives of the ASHA Special Interest Groups.
Learn more >